23982-43-6

Basic information

• Product Name: 2H-1-Benzopyran-2-one, 4-(3,4-dimethoxyphenyl)-7-hydroxy-
• Synonyms: 2H-1-Benzopyran-2-one,4-(3,4-dimethoxyphenyl)-7-hydroxy;7-Hydroxy-4-(3,4-dimethoxy-phenyl)-cumarin;7-hydroxy-4-(3,4-dimethoxyphenyl)coumarin;4-(3,4-dimethoxy-phenyl)-7-hydroxy-coumarin;4-(3,4-Dimethoxy-phenyl)-7-hydroxy-cumarin
• CAS NO: 23982-43-6
• Molecular Formula: C17H14O5
• Molecular Weight: 298.295
• Mol File: 23982-43-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 236 °C
• Boiling Point: 508.5±50.0 °C(Predicted)
• Density: 1.321±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2H-1-Benzopyran-2-one, 4-(3,4-dimethoxyphenyl)-7-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1-Benzopyran-2-one, 4-(3,4-dimethoxyphenyl)-7-hydroxy-(23982-43-6)
• EPA Substance Registry System: 2H-1-Benzopyran-2-one, 4-(3,4-dimethoxyphenyl)-7-hydroxy-(23982-43-6)

Safety Data

• Hazardous Substances Data: 23982-43-6(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 4687-37-0 ethyl 3,4-dimethoxybenzoylacetate 
• 108-46-3 recorcinol 
• 22511-06-4 3,4-dimethoxyphenylpropiolic acid 
• 99873-50-4 2,3-dibromo-3-(3',4'-dimethoxy)-phenyl ethyl propanoate 
• 20583-78-2 3,4-dimethoxy-cinnamic acid ethyl ester 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 76787-81-0 3-oxo-2-veratroyl-butyric acid ethyl ester 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 5401-66-1 2,3-Dibromo-3-(3,4-dimethoxy-phenyl)-propionic acid methyl ester 
• 30461-77-9 methyl 3,4-dimethoxycinnamate 

Downstream Products

• 854678-39-0 3-(3,4-dimethoxy-phenyl)-3-(2-hydroxy-4-methoxy-phenyl)-propionic acid ethyl ester 
• 35582-80-0 4-(3,4-dimethoxy-phenyl)-7-methoxy-chroman-2-one 
• 23982-44-7 4-(3',4'-dimethoxyphenyl)-7-methoxycoumarin 

Relevant articles and documents

Synthesis and biological evaluation of novel neoflavonoid derivatives as potential antidiabetic agents

Various substituted neoflavonoid derivatives were synthesized using sulfated montmorillonite K-10 as a catalyst. This method is environmental friendly, sustainable and economical, convenient in isolation and purification processes, with little byproducts, using earth-abundant catalysts and has relatively high yield. Those neoflavonoid derivatives were screened for antioxidant, a-glucosidase inhibitory, aldose reductase 2 (ALR2) inhibitory and advanced glycation end-product formation inhibitory effects. Most compounds exhibited significant antioxidant and advanced glycation end-product (AGE) formation inhibitory activities. It was interesting to note that out of thirty compounds, 8k and 8l were found to have greater ALR2 inhibitory activity than the standard drug quercetin. The pharmacological studies suggested neoflavonoid with adjacent 7,8-dihydroxy groups were more effective in inhibiting ALR2. Antidiabetic activity studies had shown that compounds 8l and 8m were equipotent to the standard drug glibenclamide in vivo. In summary, the target compound 8l provided a potential drug design concept for the development of therapeutic or prophylactic agents of diabetes and diabetes complications.

Antioxidant and antitumor activities of 4-arylcoumarins and 4-aryl-3,4-dihydrocoumarins

Five 4-arylcoumarins (1c-g) and twelve 3,4-dihydro-4-arylcoumarins (2a-l) were synthesized and tested for antioxidant activity, antitumor activity, toxicity and structure-activity relationships analysis. 4-Arylcoumarins and 3,4-dihydro-4-arylcoumarins tha

Synthesis and antimicrobial activities of 4-aryl-3,4-dihydrocoumarins and 4-arylcoumarins

A new series of 4-aryl-3,4-dihydrocoumarins and 4-arylcoumarins were synthesized by the reaction of substituted cinnamic acids and 3-arylpropiolic acid with the corresponding phenols. These compounds were evaluated for antibacterial activity in vitro. The